Investor Overview

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.

Upcoming Events

Date Event Details
Summary Toggle Feb 25, 2020 at 9:00 AM EST
Summary Toggle Mar 3, 2020 at 8:40 AM EST